Research programme: phospholamban regulators - Edwards Lifesciences/Sangamo TherapeuticsAlternative Names: ZFP TF therapeutic angiogenesis programme - Sangamo; ZFP TFs for cardiovascular and vascular indications - Edwards Lifesciences/Sangamo
Latest Information Update: 11 Jan 2017
At a glance
- Originator Edwards Lifesciences Corporation; Sangamo BioSciences
- Class Gene therapies; Zinc finger DNA binding proteins
- Mechanism of Action Calcium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Heart failure